Login to Your Account

Antegren's Miss In Crohn's Mars Respectable Earnings For Biogen

By Brady Huggett

Friday, July 25, 2003
Biogen Inc. and partner Elan Corp. plc released disappointing Phase III data on Antegren in an induction trial in Crohn's disease, dragging both companies' stocks down and overshadowing positive second-quarter figures for Biogen. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription